Table 3.
Gene | Subtype or normal a | Log 2 (normalized counts) b | Comparison with basal c |
---|---|---|---|
CDC2L1 | Normal | 9.39 ± 0.38 | 0.90 |
Basal | 9.51 ± 0.5 | N/A | |
Her2 | 9.45 ± 0.61 | 1 | |
Luminal A | 9.46 ± 0.4 | 1 | |
Luminal B | 9.33 ± 0.57 | 0.049 | |
CDC2L2 | Normal | 8.35 ± 0.76 | −d |
Basal | 8.37 ± 0.79 | N/A | |
Her2 | 8.49 ± 0.84 | – | |
Luminal A | 8.44 ± 0.69 | – | |
Luminal B | 8.24 ± 0.95 | – | |
CCNL1 | Normal | 10.82 ± 0.58 | 1.37 × 10 −14 |
Basal | 10.15 ± 0.56 | N/A | |
Her2 | 9.7 ± 0.49 | 9.68 × 10 −7 | |
Luminal A | 9.87 ± 0.55 | 2.17 × 10 −5 | |
Luminal B | 9.85 ± 0.49 | 2.10 × 10 −5 | |
CCNL2 | Normal | 10.79 ± 0.48 | 1.90 × 10 −11 |
Basal | 10.2 ± 0.71 | N/A | |
Her2 | 10 ± 0.73 | 1 | |
Luminal A | 10.38 ± 0.7 | 0.21 | |
Luminal B | 10.28 ± 0.7 | 1 | |
CSNK2A1 | Normal | 10.22 ± 0.2 | 5.50 × 10 −15 |
Basal | 10.74 ± 0.64 | N/A | |
Her2 | 10.75 ± 0.51 | 1 | |
Luminal A | 10.53 ± 0.39 | 9.20 × 10 −3 | |
Luminal B | 10.68 ± 0.61 | 1 | |
CSNK2A2 | Normal | 9.36 ± 0.3 | 1 |
Basal | 9.3 ± 0.39 | N/A | |
Her2 | 8.92 ± 0.56 | 3.89 × 10 −5 | |
Luminal A | 8.56 ± 0.45 | 2.06 × 10 −49 | |
Luminal B | 8.64 ± 0.47 | 2.99 × 10 −33 | |
CSNK2B | Normal | 10.96 ± 0.28 | 3.03 × 10 −38 |
Basal | 11.78 ± 0.5 | N/A | |
Her2 | 11.52 ± 0.39 | 1.91 × 10 −3 | |
Luminal A | 11.25 ± 0.42 | 4.04 × 10 −22 | |
Luminal B | 11.43 ± 0.54 | 8.24 × 10 −8 |
Her2, human epidermal growth factor receptor 2; N/A, not applicable. aNormal, n = 95; basal, n = 141; Her2, n = 67; luminal A, n = 421; luminal B, n = 192. bRNAseq data from The Cancer Genome Atlas expressed as mean ± standard deviation. cComparison with basal subtype, P value with Bonferroni correction; significant P values in bold type. dAnalysis of variance comparing CDC2L2 expression across subtypes revealed no significant differences, so no pairwise t tests were performed.